Androgen decreases osteoprotegerin expression in prostate cancer cells

K. Vandyke, P. Jackson, A. Rowe, P. J. Russell, J. M. Blair

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Osteoprotegerin (OPG), a key regulator of bone resorption, is hypothesized to have a role in prostate cancer (CaP) bone metastasis. As advanced CaP is treated by androgen ablation, we examined if androgen modulates OPG expression by CaP cell lines in vitro. Basal levels of secreted OPG protein were significantly greater in androgen-independent PC-3 cells compared with androgen-responsive LNCaP-FGC cells (P<0.001); OPG was not detected in the androgen-responsive CaP cell lines LAPC-4 or DuCaP. Treatment with 5α-dihydrotestosterone (5α-DHT) significantly decreased OPG protein levels in both PC-3 and LNCaP-FGC, with maximal suppression using 10-9 - 10-7M 5α-DHT in PC-3 (P<0.01; day 3), and using 10-10 - 10-9M 5α-DHT in LNCaP-FGC cells (Plt;0.01; day 6). OPG messenger RNA levels were not significantly altered by this 5α-DHT treatment. Co-treatment with 10-6 M flutamide blocked 5α-DHT inhibition of OPG protein expression in LNCaP-FGC cells. These data suggest that androgen may modulate OPG protein levels in CaP cells lines in vitro using a post-transcriptional mechanism.

Original languageEnglish
Pages (from-to)160-166
Number of pages7
JournalProstate Cancer and Prostatic Diseases
Issue number2
Publication statusPublished or Issued - May 2007
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this